Details of the Drug

General Information of Drug (ID: DM69G8X)

Drug Name
L-glutamine
Synonyms
NutreStore; AES-14; Aesgen-14; Glutamine (INN); L-glutamine (oral, short bowel syndrome), Emmaus; L-glutamine (topical, chemotherapy-induced mucositis), Aesgen; L-glutamine (oral, sickle cell anemia/sickle beta-0 thalassemia), Emmaus; L-glutamine (oral, sickle cell anemia/sickle beta-0 thalassemia), Emmaus/University of California Los Angeles
Indication
Disease Entry ICD 11 Status REF
Short bowel syndrome KB89.1 Approved [1]
Affected Organisms
Humans and other mammals
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 146.14
Logarithm of the Partition Coefficient (xlogp) -3.1
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 30 min []
Half-life
The concentration or amount of drug in body reduced by one-half in 1 hour []
Vd
The volume of distribution (Vd) of drug is 0.2 L/kg []
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Apoptosis Not Available LTBP1 OTR7Q75L [2]
Cytogenetic investigations Not Available GFPT1 OTQBDO45 [2]
Gastrointestinal disorders Not Available CNX1 OTLOSIX2 [2]
Chemical Identifiers
Formula
C5H10N2O3
IUPAC Name
(2S)-2,5-diamino-5-oxopentanoic acid
Canonical SMILES
C(CC(=O)N)[C@@H](C(=O)O)N
InChI
InChI=1S/C5H10N2O3/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H2,7,8)(H,9,10)/t3-/m0/s1
InChIKey
ZDXPYRJPNDTMRX-VKHMYHEASA-N
Cross-matching ID
PubChem CID
5961
ChEBI ID
CHEMBL18050
CAS Number
56-85-9
UNII
0RH81L854J
DrugBank ID
DB00130
TTD ID
D01JIA
VARIDT ID
DR00024
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Sodium-coupled neutral amino acid transporter 3 (SLC38A3) DTKWJH3 S38A3_HUMAN Substrate [3]
Putative sodium-coupled neutral amino acid transporter 7 (SLC38A7) DT2EGUN S38A7_HUMAN Substrate [3]
Sodium-coupled neutral amino acid transporter 5 (SLC38A5) DTLX28N S38A5_HUMAN Substrate [3]
Sodium-coupled neutral amino acid transporter 4 (SLC38A4) DTPJBD5 S38A4_HUMAN Substrate [3]
Sodium-coupled neutral amino acid transporter 2 (SLC38A2) DTTWL58 S38A2_HUMAN Substrate [3]
Sodium-coupled neutral amino acid transporter 1 (SLC38A1) DTD815L S38A1_HUMAN Substrate [3]
Alanine/serine/cysteine/threonine transporter 2 (SLC1A5) DTW7AE3 AAAT_HUMAN Substrate [4]
L-type amino acid transporter 1 (SLC7A5) DT48T0N LAT1_HUMAN Substrate [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Calnexin homolog 1 (CNX1) OTLOSIX2 CALX1_ARATH Drug Response [2]
Glutamine--fructose-6-phosphate aminotransferase 1 (GFPT1) OTQBDO45 GFPT1_HUMAN Drug Response [2]
Latent-transforming growth factor beta-binding protein 1 (LTBP1) OTR7Q75L LTBP1_HUMAN Drug Response [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 723).
2 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
3 Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J Biol Chem. 2011 Jun 10;286(23):20500-11.
4 High-affinity glutamate transporter GLAST/EAAT1 regulates cell surface expression of glutamine/neutral amino acid transporter ASCT2 in human fetal astrocytes. Neurochem Int. 2006 May-Jun;48(6-7):611-5.
5 Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 2009 Feb 6;136(3):521-34.